$126 Million is the total value of Opus Point Partners Management, LLC's 57 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 100.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MEIP | Exit | MEI PHARMA INC CMN | $0 | – | -30,000 | -100.0% | -0.04% | – |
AAVL | Exit | AVALANCHE BIOTECHNOLOGIES INC CMN | $0 | – | -10,000 | -100.0% | -0.34% | – |
OTIC | Exit | OTONOMY INC CMN | $0 | – | -12,000 | -100.0% | -0.36% | – |
OMER | Exit | OMEROS CORPORATION CMN | $0 | – | -20,000 | -100.0% | -0.37% | – |
KPTI | Exit | KARYOPHARM THERAPEUTICS INC CMN | $0 | – | -15,000 | -100.0% | -0.38% | – |
MGNX | Exit | MACROGENICS, INC. CMN | $0 | – | -15,000 | -100.0% | -0.40% | – |
AGIO | Exit | AGIOS PHARMACEUTICALS, INC. CMN | $0 | – | -5,000 | -100.0% | -0.40% | – |
AERI | Exit | AERIE PHARMACEUTICALS, INC. CMN | $0 | – | -20,000 | -100.0% | -0.53% | – |
XNCR | Exit | XENCOR, INC. CMN | $0 | – | -44,698 | -100.0% | -0.57% | – |
BLUE | Exit | BLUEBIRD BIO INC CMN | $0 | – | -6,000 | -100.0% | -0.61% | – |
MRTX | Exit | MIRATI THERAPEUTICS INC CMN | $0 | – | -25,000 | -100.0% | -0.61% | – |
CLDN | Exit | CELLADON CORPORATION CMN | $0 | – | -42,414 | -100.0% | -0.67% | – |
TENX | Exit | TENAX THERAPEUTICS INC CMN | $0 | – | -249,004 | -100.0% | -0.68% | – |
MNTA | Exit | MOMENTA PHARMACEUTICALS, INC. CMN | $0 | – | -60,000 | -100.0% | -0.76% | – |
GEVA | Exit | SYNAGEVA BIOPHARMA CORP CMN | $0 | – | -17,700 | -100.0% | -1.45% | – |
PCYC | Exit | PHARMACYCLICS INC CMN | $0 | – | -13,600 | -100.0% | -2.92% | – |
SLXP | Exit | SALIX PHARMACEUTICALS, LTD. CMN | $0 | – | -24,000 | -100.0% | -3.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2019-11-14 |
13F-HR | 2019-08-14 |
13F-HR | 2019-05-15 |
13F-HR | 2019-02-14 |
13F-HR | 2018-11-14 |
13F-HR | 2018-08-14 |
13F-HR | 2018-05-15 |
13F-HR | 2018-02-14 |
13F-HR/A | 2017-11-17 |
13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.